April 27, 2021
The US FDA has granted its fast-track designation for SymBio Pharmaceuticals’ brincidofovir IV for the treatment of adenovirus infection in pediatric patients, the company said on April 26. The drug maker is currently conducting a multinational PII study, mainly in...read more